Cardiol Therapeutics Inc. (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc. has made significant strides by completing patient enrollment for its Phase II MAvERIC-Pilot study on recurrent pericarditis, expecting results in Q2 2024, and receiving U.S. FDA Orphan Drug Designation. The company’s ARCHER trial investigating CardiolRx™ for acute myocarditis has passed the halfway mark in enrollment, with full completion anticipated in Q3 2024. Cardiol Therapeutics remains financially sound with sufficient funds to maintain operations until 2026, bolstering its efforts to bring new treatments for heart disease to the market.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
